We all must have come across the phase: this is why women live longer than men. These are all over the social media, where men are performing more often than not, some experiments, without gears, just for fun, "in the name of science". The caption reads: this is why women live longer. However, is there really a science to it, other than the fact that women choose to do things more safely?

In the United States, women have a life expectancy of about 80, whereas men have 75. Women outlive men and this holds true regardless of the country women live, the money they make, and other factors. In fact, it is true for most other mammals too.

Dr Dena Dubal, a professor of neurology at the University of California, San Francisco told the New York Times, "It is a very robust phenomenon all over the world, totally conserved in sickness, during famines, during epidemics, even during the times of starvation."

But what are the reasons? These reasons are often more complicated and less established. It is important to note that only because women are outliving men does not mean they are living a better life. In fact, women tend to have shorter health spans, which means the number of healthy years in a person's life is less in women than men, confirmed Bérénice Benayoun, an associate professor at the U.S.C. Leonard Davis School of Gerontology.

As per a 2021 study titled, Sex differences in frailty: Comparisons between humans and preclinical models, found that women are more physically grail than men in old age. They are also more vulnerable, especially after menopause and are at more risk of developing cardiovascular issues and Alzheimer's disease because of age.

The key is in figuring out what makes one sex more resilient or vulnerable.

Genetics

For things which do not find easy explanations, scientists look for their answers in genes. Many research, including a 2020 study titled, The sex with the reduced sex chromosome dies earlier: a comparison across the tree of life, suggests that the XX set of female sex chromosomes may impact longevity. However, there has not been any clarity on how it affects longevity.

Another 2018 study titled, Female XX sex chromosomes increase survival and extend lifespan in aging mice, which was conducted by Dr Dubal's lab, looked at genetically manipulated mice with different combinations of sex chromosomes and reproductive organs. It was found that those with two X chromosomes and ovaries lived longest, followed by mice with two X chromosomes and testes. Mice with XY chromosomes had shorter life spans.

"There was something about the second X chromosome that was protecting the mice from dying earlier in life, even if they had testes. What if there was something on that second X chromosome that was in some ways a sprinkle of the fountain of youth," says Dr Dubal. While scientists have not yet looked at this factor in humans, Dr Dubal suggests that humans have the same hormones and sex chromosomes, and similar reproductive system that could corroborate the similar findings in people.

Hormones

Plenty research has shown that estrogen is responsible for longevity also effect on the immune system. The data also shows that before menopause, the female immune system tends to do better. In fact Dr Benayoun said that males tend to do much worse in response to infection.

Another 2017 study titled, Ages at Menarche and Menopause and Reproductive Lifespan As Predictors of Exceptional Longevity in Women: The Women's Health Initiative, found that women who experienced menopause later in life over the age 50 lived longer than those who experienced it earlier.

Lifestyle and Behavior

There are also disparity in behavioral patterns between men and women. This includes smoking, drinking heavily, which can contribute significantly to mortality. Women also have more "health promoting behavior", believe experts. Women are also more likely to socialize than men and thus it protects them from detrimental effects of social isolation and loneliness. In fact, a 2023 analysis published in Jama Network, titled, Widening Gender Gap in Life Expectancy in the US, 2010-2021, found that women are less likely to die by drug overdose or suicide.

British pop star Jessie J has shared an update on her recovery after undergoing a second breast reconstruction surgery.

The 38-year-old singer-songwriter took to Instagram to share a series of photos, including one taken after her latest surgery. In the picture, she is seen wearing a hospital gown and giving a thumbs-up, with the caption, “to healing.”

The post marks Jessie’s first update since September, when she announced she would be taking a break from social media ahead of her surgery.

Jessie was diagnosed with early-stage breast cancer in 2025 and underwent a mastectomy. She announced in May 2026 that she was cancer-free.

Sharing the emotional news on Instagram, she admitted she "sobbed for hours and then exhaled for the first time in a year."

Jessie J’s Breast Cancer Diagnosis

Jessie announced her diagnosis in June 2025, shortly after performing at Capital’s Summertime Ball at London’s Wembley Stadium. She spoke candidly about her diagnosis and the surgery she would undergo.

In a video message, she shared that she had been “in and out of tests” before receiving a diagnosis of early breast cancer.

“Cancer sucks in any form,” she said, adding that she was holding on to the word “early.”

Using her characteristic dark humor, she described the surgery as “a very dramatic way to get a boob job” and told her followers, “I will come back with massive boobs and more music.”

However, she also spoke openly about the emotional toll of the diagnosis, saying, “I need to process it and talk about it” and “I need a hug.”

What Is Breast Reconstruction Surgery?

Breast reconstruction surgery aims to restore the shape and contour of the breast after a mastectomy, which involves removing the entire breast. Depending on the cancer and the treatment plan, nearby skin and lymph nodes may also be removed.

Following a mastectomy, patients may choose breast reconstruction to restore breast shape and symmetry. The procedure can be performed at the same time as the mastectomy or at a later date, depending on the patient's circumstances and treatment plan.

Why Do Some Patients Need Multiple Breast Reconstruction Surgeries?

According to the American Cancer Society, breast reconstruction often involves more than one operation. The number and type of procedures depend on the reconstruction method, the patient's needs and the desired outcome.

There are two main types of breast reconstruction:

• Implant reconstruction: A saline or silicone implant is used to rebuild the breast.
• Tissue flap reconstruction: Tissue taken from another part of the body is used to reconstruct the breast.

In some cases, surgeons combine the two approaches.

Reconstruction may be immediate, taking place during breast cancer surgery, or delayed until a later date. Both implant-based and tissue flap reconstruction can be performed using either approach.

After the initial reconstruction, some patients may undergo additional procedures to refine the breast's appearance or feel. These may include fat grafting, scar revision or procedures to recreate the nipple and areola, sometimes using medical tattooing.

Benefits And Risks Of Breast Reconstruction

Breast reconstruction can help restore breast shape and symmetry after a mastectomy. For some patients, it may also improve body image, confidence and emotional well-being. However, the benefits vary from person to person.

As with other surgical procedures, breast reconstruction carries potential risks and complications, including:

• Infection
• Fluid or blood accumulation
• Delayed wound healing
• Changes in sensation
• Implant-related complications
• Capsular contracture
• Blood clots, including deep vein thrombosis and pulmonary embolism
• Psychological effects.

Low-dose naltrexone has received plenty of attention as a strong candidate for treating people with chronic fatigue after COVID-19. But a new randomised clinical trial has found no significant improvement in fatigue, pain or any other symptoms when compared to a placebo.

The study, posted on medRxiv, examined low-dose naltrexone (LDN) in adults with post-COVID fatigue syndrome. The findings challenge hopes that an existing repurposed drug could provide relief for people whose symptoms have not subsided months after infection.

The paper has not yet undergone peer review, which means its findings have not been independently evaluated in a formal manner.

Study Based On 160 Adults With Long COVID

Also read: 'It’s The Best-Studied Vaccine In Human History': Former CDC Adviser Busts Common Myths About COVID Vaccines

160 adults aged 19 to 69 from British Columbia and Ontario, Canada participated in the trial. Participants had developed symptoms that resembled myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after a SARS-CoV-2 infection.

Researchers randomly assigned participants either low-dose naltrexone or a placebo for 16 weeks. The naltrexone dose began at 1 milligram daily and increased to a maximum of 4.5 milligrams, depending on how participants tolerated the treatment.

The main outcome was fatigue severity, which was measured using the Fatigue Severity Scale. At the end of the study, the average fatigue score was 4.2 in the LDN group and 4.4 in the placebo group.

The difference between the groups was not statistically significant, meaning the trial proved that the drug did not improve fatigue.

Researchers also found no significant differences between the groups in pain, overall ME/CFS symptoms, daily step counts or any other health aspects related to quality of life.

These results suggest that LDN did not provide any measurable benefit for the participants. The study also found that LDN was generally well tolerated over the 16-week period.

However, adverse events classified as grade 3 or higher were reported in five participants in the LDN group, or 6.2%, compared with three participants in the placebo group or 3.8%.

Why Has Low-Dose Naltrexone Attracted Interest?

Also read: 'I Never Recovered From That Crash': US Physicist Recalls Her Years-Long Battle With Long COVID

Naltrexone is an established medicine used at standard doses to treat alcohol use disorder and opioid use disorder. At much lower doses, it has been tested for conditions involving chronic pain, inflammation and fatigue.

LDN’s effects on immune signalling and inflammatory conditions have sparked interest in its potential use for long COVID, a condition that can involve fatigue, cognitive difficulties, pain, breathlessness and symptoms affecting several biological functions.

Researchers Caution

The findings apply specifically to adults with post-COVID fatigue syndrome who met the study’s criteria for ME/CFS-like symptoms.

Long COVID refers to symptoms that occur after a SARS-CoV-2 infection and cannot be explained by another diagnosis. Symptoms vary widely and may include fatigue, cognitive difficulties, breathlessness, sleep disturbances and problems with everyday activities.

Some people improve over time, while others experience prolonged illness that affects their ability to lead routine lives.

The results do not mean that long COVID symptoms are untreatable. Instead, they highlight how difficult it can be to identify effective treatments for a condition with varied symptoms.

There are currently no FDA-approved medicines specifically for long COVID, and care often focuses on managing individual symptoms.

People taking or considering naltrexone should discuss its benefits and risks with a healthcare professional rather than starting or changing treatment on their own.

Low-dose aspirin could play a key role in lowering the risk of dementia significantly in some older adults, according to a new genetic analysis. However, the benefit does not come without a complication: major bleeding.

The study, led by researchers at Monash University in Australia, is based on data from more than 13,500 participants in the ASPREE trial, which investigated the effects of low-dose aspirin in older adults. The study was published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

Researchers found that the benefit was mostly seen among people with a specific genetic trait linked with platelet count.

70% Lower Dementia Risk Was Seen Among Older Adults

Also read: Aspirin & Colon Cancer: Lancet Study Explains Why It Could Help At An Earlier Stage But Not After Spread

Platelets are small blood components that help form clots and stop bleeding. Researchers have previously examined how aggregation of platelets might contribute to dementia, but the role of genetically influenced platelet counts still remains unclear.

The researchers examined genetic scores related to platelet count and compared dementia results among participants who were either assigned aspirin or placebo.

Among people in the highest 20% of platelet count genetic scores, dementia developed in 1% of those taking aspirin, compared with 3.3% of those receiving a placebo. This represented approximately a 70% lower risk.

Lead author Dr Peter Fransquet, a research fellow at Monash University's School of Public Health and Preventive Medicine, said, “Previous trials found aspirin didn't prevent dementia when everyone was considered together.”

“Our findings suggest there may be more to the story,” he said.

Risk Of Bleeding Increased

Also read: Trump Says He ‘Psychologically’ Needs To Pop Aspirin Every Day: But Is It Actually Safe?

The benefit was accompanied by a safety concern. Among participants in the same genetic subgroup, major bleeding occurred in 4.4% of those assigned to aspirin, compared to 2.1% of those given a placebo. That is a difference of 2.3 percentage points in both dementia cases and major bleeding events. In other words, the lower dementia rate cannot be considered in isolation from the increased bleeding risk.

Aspirin reduces the ability of platelets to form clots. This can be useful for certain people who need to take precaution against cardiovascular events, but it can also increase the risk of serious bleeding, including bleeding in the gastrointestinal tract or brain.

The study therefore does not prove that aspirin offers a favourable overall balance of benefits and harms for people with this genetic profile.

Could This Help Personalise Dementia Prevention?

The researchers found that the genetic signal was not linked to established genetic risk factors for Alzheimer's disease and dementia. Instead, it pointed towards platelet factor as a possible direction for further research.

“What's particularly interesting is that the signal wasn't linked to the established genetic risk factors for Alzheimer's disease and dementia,” Fransquet said. “Instead, it's pointing us towards platelet biology and gives us a new avenue to investigate.”

The findings could contribute to more personalised approaches to dementia prevention, in which treatments are tailored to characteristics that influence how individuals respond. But the results need to be replicated in other populations and tested in a clinical trial specifically designed for people with the identified genetic profile.

Fransquet said, “People shouldn’t start taking aspirin to prevent dementia on the basis of this study without consulting with their doctor, particularly given the increased risk of serious bleeding,” he said.